



► Additional material is published online only. To view please visit the journal online (http://dx.doi.org/10.1136/ bjsports-2015-095424)

¹Faculty of Health Sciences, Clinical and Rehabilitation Sciences Research Group and Discipline of Physiotherapy, University of Sydney, Sydney, Australia ²Department of Medicine, St Joseph's Health Care Centre, Toronto, Canada ³Department of Rehabilitation, Reade, Centre for Rehabilitation and Rheumatology, Amsterdam, The Netherlands ⁴Department of Physiotherapy, Melbourne School of Health Sciences, University of Melbourne, Melbourne, Australia

Correspondence to

Dr Martin Van der Esch, Department of Rehabilitation, Reade, Centre for Rehabilitation and Rheumatology, dr. J. van Breemenstraat 2, Amsterdam 1056AB, The Netherlands; m.vd.esch@reade.nl

This review is an abridged version of a Cochrane Review previously published in the *Cochrane Database of Systematic Reviews* 2015;1: 10.1002/14651858.CD004376 (see www.thecochranelibrary. com for information).

Accepted 17 August 2015 Published Online First 24 September 2015



To cite: Fransen M, McConnell S, Harmer AR, et al. Br J Sports Med 2015;49:1554–1557.

Exercise for osteoarthritis of the knee: a Cochrane systematic review

Marlene Fransen,¹ Sara McConnell,² Alison R Harmer,¹ Martin Van der Esch,³ Milena Simic,¹ Kim L Bennell⁴

ABSTRACT

Objective To determine whether land-based therapeutic exercise is beneficial for people with knee osteoarthritis (OA) in terms of reduced joint pain or improved physical function and quality of life. **Methods** Five electronic databases were searched, up until May 2013. Randomised clinical trials comparing some form of land-based therapeutic exercise with a non-exercise control were selected. Three teams of two review authors independently extracted data and assessed risk of bias for each study. Standardised mean differences immediately after treatment and 2–6 months after cessation of formal treatment were separately pooled using a random effects model.

Results In total. 54 studies were identified. Overall. 19 (35%) studies reported adequate random sequence generation, allocation concealment and adequately accounted for incomplete outcome data. However, research results may be vulnerable to selection, attrition and detection bias. Pooled results from 44 trials indicated that exercise significantly reduced pain (12 points/100; 95% CI 10 to 15) and improved physical function (10 points/100; 95% CI 8 to 13) to a moderate degree immediately after treatment, while evidence from 13 studies revealed that exercise significantly improved quality of life immediately after treatment with small effect (4 points/100: 95% CI 2 to 5). In addition, 12 studies provided 2-month to 6-month post-treatment sustainability data which showed significantly reduced knee pain (6 points/100; 95% CI 3 to 9) and 10 studies which showed improved physical function (3 points/100; 95% CI 1 to 5).

Conclusions Among people with knee osteoarthritis, land-based therapeutic exercise provides short-term benefit that is sustained for at least 2–6 months after cessation of formal treatment.

INTRODUCTION

Osteoarthritis (OA), the most common rheumatic disease, primarily affects the articular cartilage and the subchondral bone of a synovial joint, eventually resulting in joint failure. People with progressive symptomatic knee OA experience pain and increasing difficulty with daily functional activities. In fact, knee OA bears more responsibility than any other disease for disability in walking, stair climbing and housekeeping.^{1–3} Currently, no cure for OA is known. However, disease-related factors, such as impaired muscle function and reduced fitness, are potentially amenable to exercise therapy.^{4–5}

Exercise therapy takes a multitude of forms and results in numerous systemic and local effects, some of which have been investigated among people with

knee OA. Therapeutic exercise covers a range of targeted physical activities that directly aim to improve muscle strength, neuromotor control, joint range of motion and aerobic fitness. One of the main aims of exercise is to improve muscle strength, given that weakness is common in knee OA. Strength training of sufficient dosage can address muscle weakness by improving muscle mass and/or recruitment. However, among patient groups, pain must be considered and may be a barrier, hence leading to underdosage of the strength stimulus. Enhanced strength of the lower limb may lessen internal knee forces, reduce pain and improve physical function.⁶⁻⁸ Increased muscle strength may modify biomechanics, resulting in a decreased joint loading rate or localised stress in the articular cartilage, thereby playing an important role in delaying initiation and ameliorating progression of knee OA.⁹⁻¹⁴ Improved fitness may enhance quality of life by allowing a greater range of available daily tasks, thereby improving physical function.

The objective of this systematic review was to determine whether land-based therapeutic exercise is beneficial for people with knee OA in terms of reduced joint pain or improved physical function and quality of life.

METHODS

The search strategy identified all randomised or quasi-randomised controlled trials (RCTs), published in the English language, that compared a group undertaking some form of land-based therapeutic exercise with a non-exercise group. Participants given an established diagnosis of knee OA according to accepted criteria,¹⁵ or who selfreported knee OA on the basis of chronic joint pain (with or without radiographic confirmation) were included. Any land-based non-perioperative therapeutic exercise regimens aimed at relieving the symptoms of OA, regardless of content, duration, frequency or intensity were included. The comparator (control) group could be an active (given any non-exercise intervention) or no treatment (including waiting list) group.

In accordance with international consensus regarding the core set of outcome measures for phase III clinical trials in OA,¹⁶ each RCT had to include assessment of at least one of the following criteria: (1) knee pain, (2) self-reported physical function and (3) quality of life. If provided, the number of participants experiencing adverse events was noted.

Five electronic databases were searched from inception to May 2013: MEDLINE, EMBASE, the



Cochrane Central Register of Controlled Trials (CENTRAL), the Cumulative Index to Nursing and Allied Health Literature (CINAHL) and the Physiotherapy Evidence Database (PEDro). Also included was a search of ClinicalTrials.gov (http://www. ClinicalTrials.gov) and the WHO trials portal (http://www.who. int/ictrp/en/).

Three teams of two review authors (MF, SMcC, ARH, MVdE, MS, KLB) independently screened retrieved clinical studies for inclusion. If agreement was not achieved at any stage, a third review author from one of the other two teams adjudicated. Those teams extracted data from all included studies and conducted the risk of bias assessment. If agreement was not achieved at any stage, a third review author from one of the other two teams adjudicated. If a trial provided data from more than one pain scale, data were extracted from the pain scale that was highest on a list according to a previously described hierarchy of pain-related outcomes.¹⁷ ¹⁸ Data on more than one physical function scale, when reported in a trial, were extracted according to a hierarchy format (eg, WOMAC or other functional scale). If data on more than one quality of life scale were reported in a trial, data were extracted according to a hierarchy format (eg, SF-12 or other quality of life scale). Risk of bias was assessed in accordance with methods recommended by The Cochrane Collaboration. Each potential source of bias was graded as high, low or unclear. If random sequence generation, allocation concealment and incomplete outcome data domains were adequately met by a study, the overall risk of bias on pain and physical function was judged as 'low' for that study. All other studies were categorised as 'unclear' or 'high' risk of bias. If participants were stated to be blinded to treatment allocation, the study was considered as low risk for detection bias on pain and physical function.

As studies used a variety of continuous scales to evaluate pain, physical function and quality of life outcomes, a unit-less measure of treatment effect size was needed to allow the results of various RCTs to be combined. Standardised mean differences (SMDs) were used to calculate treatment effect sizes from the end of treatment, or change scores and related SD scores, when possible. Treatment effect size therefore is a unit-less measure providing an indication of size of effect in terms of its variability. Outcomes pooled using SMDs were re-expressed as equivalent mean differences by multiplying by a representative control group (high weighting in pooled analyses) baseline SD. The Mantel-Haenszel OR was pooled to calculate the effects of treatment allocation on study withdrawal before the first outcome assessment.

Heterogeneity was assessed in a random-effects model, and overall effects were adjusted to include an estimate of the degree of variation between studies, or heterogeneity, in intervention effect (τ^2) .¹⁹ The impact of heterogeneity on meta-analysis results was quantified by the I² statistic. This statistic describes the percentage of variability in effect estimates that is due to heterogeneity rather than to chance¹⁹: 30-60% probably represents moderate heterogeneity, and >50% is usually considered as representing substantial heterogeneity. For studies published after 1 July 2005, the Clinical Trials Register at the International Clinical Trials Registry Platform of the WHO (http://apps.who.int/ trialssearch) was screened to obtain the a priori trial protocol. The GRADEpro software and the five GRADE (Grades of Recommendation, Assessment. Development and Evaluation) considerations (study limitations, consistency of effect, imprecision, indirectness and publication bias) were used to assess the quality of a body of evidence for stated outcomes.²⁰ ²¹Finally, with sensitivity analysis, the effects

of (1) potential selection and attrition bias on immediate posttreatment pain and physical function outcomes and (2) the effect of potential detection bias on immediate post-treatment pain and physical function outcomes were assessed.

Subgroup analyses were conducted to determine the sustainability of treatment effects, as well as to determine if the size of treatment effect was mediated by exercise content, number of face-to-face sessions or the method of treatment delivery.

RESULTS

Study characteristics

Of 212 retrieved RCTs identified by the literature search, 54 met the inclusion criteria.^{22–75} Among these, marked variability was noted with regard to study participants recruited, timing of outcomes assessments, exercise interventions assessed and important aspects of study methodology. Most studies recruited between 50 and 150 participants. However, 19 (35%) studies recruited fewer than 25 participants in one or both allocation groups,^{23–25} ^{29–31} ³⁵ ³⁹ ⁵⁰ ⁵² ⁵⁸ ⁵⁹ ^{63–69} whereas five studies recruited more than 200 participants,^{22 45} ⁴⁸ ⁴⁹ ⁷⁰ one of which recruited 750 participants.⁷⁰

Sample recruitment varied widely, with studies recruiting exclusively community volunteers, ²³ ²⁶ ²⁷ ²⁹ ³⁴ ³⁶ ³⁸ ⁴⁴ ⁴⁹ ⁵³ ⁶⁰⁻⁶² ⁶² ⁶⁴ ⁷⁴ patients drawn from specialist rheumatology or orthopaedic clinics, ²⁸ ³⁰ ³³ ³⁵ ⁴⁶ ⁴⁷ ⁵⁴ ⁶⁶ ⁶⁸ ⁷¹ ⁷⁵ a mix of community volunteers and patients from specialist clinics or patients referred by general practitioners. ²² ²⁵ ⁴⁸ ⁵⁰

A wide range of therapeutic exercise programmes were assessed. Variability was found in delivery mode, type of exercise, and treatment 'dosage' (duration, frequency, intensity) and many studies did not provide a clear rationale for their choice. With regard to treatment duration, monitored treatment sessions, presented in individual or class-based format, ranged from 20 to 60 min. Exercise frequency for monitored classes or for individual clinic sessions in most studies was two to three times per week but varied between one²⁸ 41 49 72 75</sup> to five times per week.²³ Intensity achieved during strength training using free or limb weights or Theraband was commonly a 10-repetition maximum with varying numbers of sets^{27 31 34 53} or was at least moderate.³⁰ 72 74</sup> Aerobic exercise training, achieved via walking or cycling programmes, ranged from low^{25 69} to moderate^{34 37 44 50 57 59 61 64} intensity.

According to the methodological quality assessment, a total of 19 of 54 studies (35%) could be considered as achieving 'low risk of bias' from the published report.²² ²⁴ ²⁶ ³⁴ ³⁵ ³⁷ ³⁸ ⁴⁸ ^{52–55} ⁵⁷ ⁶² ⁷⁰ ⁷¹ ⁷³ ⁷⁴ Only 4 of the 54 included studies claimed blinding of study participants.²⁶ ³¹ ³⁶ ⁶²

Pooled results of 44 studies (see online supplementary table S1) demonstrated statistically significant benefit of exercise on pain immediately post-treatment, with an SMD of 0.49 (95% CI 0.39 to 0.59). This effect size would be considered moderate⁷⁶ and was equivalent to a reduction of 12 points (95% CI 10 to 15 points) on a 0 to 100-point pain scale (0 indicating no pain). Between-study heterogeneity was moderate (I^2 =47%). No significant difference was noted between the SMD extrapolated from change scores and from end of treatment scores (p=0.77; I^2 =0%).

Pooled results of 44 studies (see online supplementary table S2) demonstrated statistically significant benefit of exercise on physical function immediately post-treatment, with an SMD of 0.52 (95% CI 0.39 to 0.64). This effect size would be considered moderate⁷⁶ and was equivalent to an improvement of 10 points (95% CI 8 to 13 points) on a 0–100-point scale. Between-study heterogeneity was substantial (I^2 =68%). No

significant difference was noted between change and end of

treatment scores (p=0.36; $I^2=0\%$). Pooled results of 13 studies (see online supplementary table S3) demonstrated statistically significant benefit of exercise on quality of life immediately post-treatment, with an SMD of 0.28 (95% CI 0.15 to 0.40). This effect size would be considered small⁷⁶ and was equivalent to an improvement of four points (95% CI 2 to 5 points) on a 0-100-point scale. Between-study heterogeneity was negligible ($I^2=0\%$). No significant difference was noted between change scores and end of treatment scores (p=0.86; $I^2=0\%$).

Pooled results from 12 studies²⁶ 30 40 44 45 48 55 60 62 69 75 77 demonstrated a statistically significant benefit (SMD 0.24, 95% CI 0.14 to 0.35) of exercise on pain at 2–6 months postexercise training. This effect size would be considered small and was equivalent to a reduction of six (95% CI 3 to 9) points on a 0-100-point scale. There was no between-study heterogeneity $(I^2=0\%)$. No significant difference was noted between change

scores and end of treatment scores (p=0.40; $I^2=0\%$). In 10 studies,^{26 30 40 44 45 55 60 62 75 77} pooled results demonstrated a statistically significant benefit (SMD 0.15, 95% CI 0.04 to 0.26) of exercise on physical function at 2-6 months postexercise training. This effect size would be considered small and was equivalent to an improvement of 3 (95% CI 1 to 5) points on a 0-100-point scale. There was no between-study heterogeneity ($I^2=0\%$). No significant difference was noted between change scores and end of treatment scores (p=0.95; $I^2 = 0\%$).

In six studies,²² ⁴² ⁴³ ⁵⁸ ⁶³ ⁷⁰ a non-significant effect (SMD 0.08, 95% CI -0.15 to 0.30) on pain after more than 6 months was found. The between-study heterogeneity was moderate $(I^2=43\%)$. No significant difference was noted between change scores and end of treatment scores (p=0.95; $I^2=0\%$). Pooled results of seven studies²² 42 43 58 59 63 70 demonstrated statistically significant benefit (SMD 0.20, 95% CI 0.08 to 0.32) on physical function after more than 6 months. Between-study heterogeneity was absent ($I^2=0\%$). No significant difference was noted between change scores and end of treatment scores $(p=0.95; I^2=0\%).$

The magnitude of the immediate treatment effect for both pain and physical function increased with the number of face-to-face contact occasions with the healthcare professional supervising or monitoring the exercise programme. However, the difference between fewer than 12 occasions and 12 or more occasions failed to reach statistical significance for pain (p=0.15) and for physical function (p=0.09), respectively. Pooled analysis demonstrated that each of the treatment delivery modes (ie, individual treatments, class-based programmes, and 'home' programmes) provided significant reductions in pain and physical function but with no significant difference between the modes for pain (p=0.14) or physical function (p=0.06). While each type of exercise (quadriceps strengthening only, lower limb strengthening, combination strengthening and aerobic exercise, walking programmes and 'others') reduced pain and improved physical function, there was no statistical difference between the exercise training types on pain (p=0.37) and physical function (p=0.09).

Only 11 RCTs specifically reported on adverse events.²² ²⁶ ³¹ ³⁵ ³⁶ ³⁸ ⁴⁵ ⁴⁷ ⁵³ ⁵⁵ ⁷³ All reported events were related to increased back, hip or knee pain among participants allocated to exercise. No serious adverse events were reported in any of the included studies.

Sensitivity analyses showed that the risk of selection and attrition bias was 'low' in 14 studies (1458 participants) for pain

Br J Sports Med: first published as 10.1136/bjsports-2015-095424 on 24 September 2015. Downloaded from http://bjsm.bmj.com/ on April 27, 2024 by guest. Protected by copyright

and for physical function (14 studies, 1456 participants).²⁴ ²⁶ ²⁷ ³⁴ ³⁵ ³⁷ ³⁸ ^{52–55} ⁷¹ ⁷³ ⁷⁴ All other studies were categorised as 'unclear' or 'high' risk of bias (30 studies, 2029 and 2457 participants, respectively). The risk of detection bias for pain and physical function was 'low' in three studies with 226 participants,^{26 31 36} indicating that participants were stated to be blinded to treatment allocation. All other included studies were categorised as 'unclear' or 'high' risk of bias (41 studies, 3261 and 3687 participants, respectively).

DISCUSSION

This systematic review is an update of a previous Cochrane review, published in 2008, which included 32 RCTs. An additional 22 RCTs have been included in this update for a total of 54 trials, providing data from 5362 participants for outcomes on pain and from 5222 participants for outcomes on physical function. Overall, meta-analysis demonstrated that land-based therapeutic exercise programmes resulted in an immediate mean treatment benefit for knee pain, physical function and quality of life. These mean immediate treatment benefits, extracted from 44 RCTs involving 3537 participants for pain and 3913 participants for physical function, would be considered moderate. Treatment benefit for quality of life, extracted from 13 trials involving 1073 participants, would be considered small. The benefit for pain is comparable with reported estimates for current simple analgaesics and non-steroidal anti-inflammatory drugs taken for knee pain.⁷⁷ Similar results were found for physical function when restricted to the 14 studies, with a total of 1456 participants, evaluated as having low risk of bias. The pain-relieving benefit of exercise declined at 2-6 months postexercise but was still significant, as evidenced in 12 studies involving 1468 participants. However, pain benefits were lost longer than 6 months postexercise, as was found in six studies. A small but significant treatment benefit for physical function remained 2-6 months following exercise, as extracted from 10 studies involving 1279 participants, as well as at time points longer than 6 months, as evidenced in seven studies. These results suggest that although the pain-relieving benefit of exercise therapy is not maintained six or more months after treatment, improvements in physical function are better sustained.

This review highlighted the variety in content of exercise programmes. A range of exercise types can be utilised in clinical practice, with lower limb muscle strengthening and general aerobic exercise recommended by most international guidelines.^{12 77} Few studies have attempted to directly compare different types of exercise. One study compared aerobic walking and muscle strengthening, but lack of study power for this particular research question led to inconclusive results.³⁴Two other studies compared different strengthening regimens: weight bearing quadriceps exercises versus non-weight bearing quadriceps exercises in one study,⁴⁷ and concentric-eccentric strengthening exercises versus isometric strengthening exercises in the other.65 Neither study found significant differences in effect between types of strengthening exercises. It is interesting to note that meta-analyses also could not demonstrate significant differences in the magnitude of treatment effects for pain and physical function between the various exercise programmes. However, for both pain and physical function, exercise programmes classified as 'other' (which included Tai Chi or complex non-specific exercise programmes involving coordination, stretching or balancing exercises) yielded small benefits and seemed to be less effective than strengthening and aerobic exercise.

The magnitude of the treatment effect for pain and physical function was influenced by the delivery mode such as the number of face-to-face contact occasions with the healthcare professional who was supervising or monitoring the exercise programme. However, unlike in the previous Cochrane review,⁸ the difference between fewer than 12 and 12 or more occasions failed to reach statistical significance; this is likely due to considerable between study heterogeneity. Taken together, results suggest that most people with knee OA need some form of ongoing monitoring or supervision to optimise clinical benefits of exercise treatment.

Exercise 'dosage,' which is a factor of programme duration, frequency and intensity, varied considerably between the studies included in this review. Even if dosages were similar, uncertainty may still be inherent. Prescribed dosage may not be translated into actual dosage as it is dependent on individual effort (and hence intensity) during each session; and prescribed dosage is also dependent on effort during testing and retesting sessions. The influence of programme duration on dosage is difficult to quantify, with simple addition not providing a sufficient physiologically plausible model. Only one of the included studies attempted to evaluate the influence of exercise dosage on outcomes by comparing high-intensity and low-intensity resistance training of the knee flexor and extensor muscles while controlling for total exercise workload.⁴⁶ That study found no difference between high-intensity and low-intensity strength training in improving clinical effects.

Overall quality of the body of evidence was assessed as high when the GRADE approach was applied for pain and quality of life. Although selection, attrition and detection bias may have resulted in overestimation of the effect sizes, we did not consider it substantial enough to downgrade the evidence. Evidence underpinning physical function was moderate and was downgraded because of imprecision (marked heterogeneity between study findings). For immediate post-treatment pain and physical function, 14 of 42 studies (33%) were categorised as having low risk of selection and attrition bias (random sequence generation, allocation concealment and incomplete outcome data domains adequately met).

Treatment effect size for many of the studies was modest. Multifaceted interventions that incorporate exercise strategies into patient care may provide greater benefit and should be tested. Future studies are needed to: (1) identify possible predictors of patient responsiveness to therapeutic exercise, such as radiographic disease severity, symptom duration, outcomes expectancy, psychological well-being, obesity, knee stability, etc, (2) develop multiarmed placebo-controlled RCTs to help provide evidence of optimal exercise content and dosage, and (3) assess the long-term effectiveness of exercise for people with knee OA in terms of structural disease progression.

Some important caveats to this review must be stated. First, given that the comparator in many studies was a no-treatment control group, and that blinding of participants was not performed in almost all trials, the well-documented strong placebo effects for self-reported outcomes in knee OA⁷⁸ have not been controlled for in the exercise studies. Thus it is not possible to determine the exact magnitude of beneficial effects directly arising from exercise per se. The second issue concerns the responsiveness of self-reported pain and physical function measures. Many of the studies included in this systematic review recruited a majority of participants with early or mild symptomatic disease. Although people with early disease frequently demonstrate reduced muscle strength and aerobic capacity compared with their age-matched and gender-matched peers without symptomatic OA, these physiological impairments often are not yet large enough to translate into reportable difficulties on

simple questionnaires. Lack of reportable difficulties would considerably reduce the potential range of improvement that was possible (ceiling effect) on self-report questionnaires among people with early or mild disease.

Several limitations of this review have been identified. Although we conducted an extensive literature search, because resources were limited, we extracted data only from studies published in the English language, potentially excluding other important evidence. Four studies were published in a language other than English,⁷⁹⁻⁸² and we were unable to source full text for two studies.^{83 84} These studies await classification. However, the possibility of publication bias could not be excluded, as we did not attempt to retrieve unpublished studies. The effectiveness of exercise was investigated only for measures of self-reported pain, physical function and quality of life. However, regular exercise has been demonstrated to offer many other overall physical and mental health benefits, apart from those related to OA-induced disease impairments. Therefore this review likely underestimates the overall beneficial effects of exercise amongst people with knee OA, which is consistent with previously pub-lished systematic reviews.⁸⁵⁸⁶ Mediating effects of exercise dosage and disease severity on the effectiveness of exercise could not be ascertained because of large variability in reported data.

Conclusions

High-quality evidence suggests that land-based therapeutic exercise provides benefit in terms of reduced knee pain and improved quality of life and moderate-quality evidence of improved physical function among people with knee OA. Healthcare professionals and people with OA can be reassured that any type of exercise programme that is performed regularly and is closely monitored by healthcare professionals can improve pain, physical function and quality of life related to knee OA in the short term.

What are the new findings?

- High-quality evidence suggests that land-based therapeutic exercise provides benefit in terms of reduced knee pain and improved quality of life and moderate-quality evidence of improved physical function among people with knee osteoarthritis.
- It can be assured that any type of exercise programme that is performed regularly and is closely monitored can improve pain, physical function and quality of life related to knee OA in the short term.
- The magnitude of immediate treatment effects of exercise on pain and physical function increases with the number of face-to-face contact occasions with the healthcare professional.
- Mediating effects of exercise dosage and disease severity on the effectiveness of exercise could not be ascertained because of large variability in reported data.

Competing interests None.

Provenance and peer review Not commissioned; internally peer reviewed.

REFERENCES

1 Davis MA, Ettinger WH, Neuhaus JM, *et al.* Knee osteoarthritis and physical functioning: evidence from the NHANES 1 epidemiologic followup study. *J Rheumatol* 1991;18:591–8.

- 2 Guccione AA, Felson DT, Anderson JJ, *et al*. The effects of specific medical conditions on the functional limitations of elders in the Framingham study. *Am J Public Health* 1994;84:351–8.
- 3 van Dijk GM, Dekker J, Vennhof C, et al. Course of functional status and pain in osteoarthritis of the hip or knee: a systematic review of the literature. Arthritis Rheum 2006;55:779–85.
- 4 Buchner DM, Beresford SAA, Larson EB, et al. Effects of physical activity on health status in older adults II: Intervention studies. Ann Rev Publ Health 1992:13:469–88.
- 5 Fiatarone MA, Evans WJ. The etiology and reversibility of muscle dysfunction in the aged. J Gerontol 1993;48:77–83.
- 6 Bennell KL, Hunt MA, Wrigley TV, et al. Role of muscle in the genesis and management of knee osteoarthritis. *Rheum Dis Clin North Am* 2008;34:731–54.
- 7 Dekker J. Exercise and physical functioning in osteoarthritis; medical, neuromuscular and behavioral perspectives. Berlin: Springer-Verlag, 2013.
- 8 Fransen M, McConnell S, Harmer AR, et al. Exercise for osteoarthritis of the knee. Cochrane Database Syst Rev 2015;1:CD004376.
- 9 Cooper C. Occupational activity and the risk of osteoarthritis. *J Rheumatol* 1995;22:10–12.
- 10 Felson DT. Weight and osteoarthritis. J Rheumatol 1995;22:7-9.
- 11 Kujala UM, Kettunen J, Paananen H, *et al*. Knee osteoarthritis in former runners, soccer players, weight lifters, and shooters. *Arthritis Rheum* 1995;38:539–46.
- McAlindon TE, Bannuru RR, Sullivan MC, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthr Cartil 2014;22:363–88.
 Slemenda C, Brandt KD, Heilman DK, et al. Quadriceps weakness and osteoarthritis
- of the knee. *Ann Intern Med* 1997;12:97–104. 14 Zhang Y, Glynn RJ, Felson D. Musculoskeletal disease research: should we analyze
- 14 Zhang Y, Giynn RJ, Felson D. Musculoskeletal disease research: should we analyze the joint or the person? J Rheumatol 1996;23:1130–4.
- 15 Altman RD. Criteria for the classification of clinical osteoarthritis. *J Rheumatol* 1991;18(Suppl 27):10–12.
- 16 Bellamy N, Kirwan J, Boers M, et al. Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip and hand osteoarthritis. Consensus development at OMERACT III. J Rheumatol 1997;24:799–802.
- 17 Jüni P, Reichenbach S, Dieppe P. Osteoarthritis: rational approach to treating the individual. *Best Pract Res Clin Rheumatol* 2006;20:721–40.
- 18 Reichenbach S, Sterchi R, Scherer M, et al. Meta-analysis: chondroitin for osteoarthritis of the knee or hip. Ann Intern Med 2007;146:580–90.
- 19 Deeks JJ, Higgins JPT, Altman DG. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins J, Green S, eds. *Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2: The Cochrane Collaboration*. The Cochrane Collaboration, 2011. http://www.cochrane-handbook.org
- 20 Schünemann HJ, Oxman AD, Higgins JPT, et al. Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, http://www.cochrane-handbook.org
- 21 Schünemann HJ, Oxman AD, Vist GE, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. http://www.cochranehandbook.org
- 22 Abbott JH, Robertson MC, Chapple C, et al. Manual therapy, exercise therapy, or both, in addition to usual care, for osteoarthritis of the hip or knee: a randomized controlled trial. I: Clinical effectiveness. Osteoarthr Cartil 2013;21:525–34.
- 23 An B, Dai K, Zhu Z, et al. Baduanjin alleviates the symptoms of knee osteoarthritis. J Altern Complement Med 2008;14:167–74.
- 24 Baker KR, Nelson ME, Felson DT, *et al.* The efficacy of home based progressive strength training in older adults with knee osteoarthritis: a randomized controlled trial. *J Rheumatol* 2001;28:1655–65.
- 25 Bautch JC, Malone DG, Vailas AC. Effects of exercise on knee joints with osteoarthritis: a pilot study of biologic markers. *Arthritis Care Res* 1997;10:48–55.
- 26 Bennell KL, Hinman RS, Metcalf BR, et al. Efficacy of physiotherapy management of knee joint osteoarthritis: a randomised, double blind, placebo controlled trial. Ann Rheum Dis 2005;64:906–12.
- 27 Bennell KL, Hunt MA, Wrigley TV, *et al*. Hip strengthening reduces symptoms but not knee load in people with medial knee osteoarthritis and varus malalignment: a randomised controlled trial. *Osteoarthr Cartil* 2010;18:621–8.
- 28 Bezalel T, Carmeli E, Katz-Leurer M. The effect of a group education programme on pain and function through knowledge acquisition and home-based exercise among patients with knee osteoarthritis: a parallel randomised single-blind clinical trial. *Physiotherapy* 2010;96:137–43.
- 29 Brismée J, Paige RL, Chyu M, et al. Group and home-based Tai Chi in elderly subjects with knee osteoarthritis: a randomized controlled trial. *Clinic Rehab* 2007;21:99–111.
- 30 Bruce-Brand RA, Walls RJ, Ong JC, et al. Effects of home-based resistance training and neuromuscular electrical stimulation in knee osteoarthritis: a randomized controlled trial. BMC Musculoskelet Dis 2012;13:118.
- 31 Chang TF, Liou TH, Chen CH, et al. Effects of elastic-band exercise on lower-extremity function among female patients with osteoarthritis of the knee. *Disabil Rehabil* 2012;34:1727–35.

- 32 Deyle GD, Henderson NE, Matekel RL, et al. Effectiveness of manual physical therapy and exercise in osteoarthritis of the knee. Ann Intern Med 2000;132:173–81.
- 33 Doi T, Akai M, Fujino K, et al. Effect of home exercise of quadriceps on knee osteoarthritis compared with nonsteroidal antiinflammatory drugs: a randomized controlled trial. Am J Physic Med Rehabil 2008;87:258–69.
- 34 Ettinger WH, Burns R, Messier SP, et al. A randomized trial comparing aerobic exercise and resistance exercise with a health education program in older adults with knee osteoarthritis. The Fitness Arthritis and Seniors Trial (FAST). JAMA 1997;277:25–31.
- 35 Foley A, Halbert J, Hewitt T, et al. Does hydrotherapy improve strength and physical function in patients with osteoarthritis—a randomised controlled trial comparing a gym based and a hydrotherapy based strengthening programme. Ann Rheum Dis 2003;62:1162–7.
- 36 Foroughi N, Smith RM, Lange AK, et al. Lower limb muscle strengthening does not change frontal plane moments in women with knee osteoarthritis: a randomized controlled trial. *Clin Biomech* 2011;26:167–74.
- 37 Fransen M, Crosbie J, Edmonds J. Physical therapy is effective for patients with osteoarthritis of the knee: a randomized controlled trial. J Rheumatol 2001;28:156–64.
- 38 Fransen M, Nairn L, Winstanley J, et al. Physical activity for osteoarthritis management: a randomised controlled clinical trial evaluating hydrotherapy and Tai Chi classes. Arthritis Care Res 2007;57:407–14.
- 39 Gür H, Çakin N, Akova B, *et al.* Concentric versus combined concentric-eccentric isokinetic training: effects on functional capacity and symptoms in patients with osteoarthrosis of the knee. *Arch Phys Med Rehabil* 2003;83:308–16.
- 40 Hay EM, Foster NE, Thomas E, et al. Effectiveness of community physiotherapy and enhanced pharmacy review for knee pain in people aged over 55 presenting to primary care: pragmatic randomised trial. BMJ 2006;333:995.
- 41 Hopman-Rock M, Westhoff M. The effects of a health educational and exercise program for older adults with osteoarthritis of the hip or knee. J Rheumatol 2000;27:1947–54.
- 42 Huang M-H, Lin Y-S, Yang R-C, *et al*. A comparison of various therapeutic exercises on the functional status of patients with knee osteoarthritis. *Semin Arthritis Rheum* 2003;32:398–406.
- 43 Huang M-H, Yang R-C, Lee C-L, et al. Preliminary results of integrated therapy for patients with knee osteoarthritis. Arthritis Care Res 2005;53:812–20.
- 44 Hughes SL, Seymour RB, Campbell R, *et al.* Impact of the Fit and Strong intervention on older adults with osteoarthritis. *Gerontologist* 2004;44:217–28.
- Hurley MV, Walsh NE, Mitchell HL, *et al.* Clinical effectiveness of a rehabilitation program integrating exercise, self-management, and active coping strategies for chronic knee pain: a cluster randomized trial. *Arthritis Rheum* 2007;57:1211–19.
- 46 Jan M, Lin J, Liau J, et al. Investigation of clinical effects of high- and low-resistance training for patients with knee osteoarthritis: a randomized controlled trial. *Phys Ther* 2008;88:427–36.
- 47 Jan M, Lin C, Lin Y, et al. Effects of weight-bearing versus nonweight-bearing exercise on function, walking speed, and position sense in participants with knee osteoarthritis: a randomized controlled trial. Arch Phys Med Rehabil 2009;90:897–904.
- 48 Jenkinson CM, Doherty M, Avery AJ, et al. Effects of dietary intervention and quadriceps strengthening exercises on pain and function in overweight people with knee pain: randomised controlled trial. BMJ 2009;339:b3170.
- 49 Kao M-J, Wu M-P, Tsai M-W, et al. The effectiveness of a self-management program on quality of life for knee osteoarthritis (OA) patients. Arch Gerontol Geriatrics 2012;54:317–24.
- 50 Keefe FJ, Blumenthal J, Baucom D, et al. Effects of spouse-assisted coping skills training and exercise training in patients with osteoarthritic knee pain: a randomized controlled study. Pain 2004;110:539–49.
- 51 Kovar PA, Allegrante JP, MacKenzie CR, *et al.* Supervised fitness walking in patients with osteoarthritis of the knee. *Ann Intern Med* 1992;116:529–34.
- 52 Lee H-J, Park H-J, Chae Y, *et al.* Tai Chi Qigong for the quality of life of patients with knee osteoarthritis: a pilot, randomized, waiting list controlled trial. *Clinic Rehabil* 2009;23:504–11.
- 53 Lim B-W, Hinman RS, Wrigley TV, et al. Does knee malalignment mediate the effects of quadriceps strengthening on knee adduction moment, pain, and function in medial knee osteoarthritis? A randomized controlled trial. Arthritis Care Res 2008;59:943–51.
- 54 Lin D, Lin CJ, Lin Y, et al. Efficacy of 2 non-weight bearing interventions, proprioception training versus strength training, for patients with knee osteoarthritis: a randomized clinical trial. J Orthop Sports Phys Ther 2009;39:450–7.
- 55 Lund H, Weile U, Christensen R, *et al*. A randomized controlled trial of aquatic and land-based exercise in patients with knee osteoarthritis. *J Rehabil Med* 2008;40:137–44.
- 56 Maurer BT, Stern AG, Kinossian B, et al. Osteoarthritis of the knee: isokinetic quadriceps exercise versus an educational intervention. Arch Physic Med Rehabil 1999;80:1293–9.
- 57 Messier SP, Loeser RF, Miller GD, *et al.* Exercise and dietary weight loss in overweight and obese older adults with knee osteoarthritis. *Arthritis Rheum* 2004;50:1501–10.

Review

- 58 Mikesky AE, Mazzuca SA, Brandt KD, et al. Effects of strength training on the incidence and progression of knee osteoarthritis. Arthritis Care Res 2006;55:690–9.
- 59 Minor MA, Hewett JE, Webel RR, et al. Efficacy of physical conditioning exercise in patients with rheumatoid arthritis and osteoarthritis. Arthritis Rheum 1989;32:1396–405.
- 60 O'Reilly SC, Muir KR, Doherty M. Effectiveness of home exercise on pain and disability from osteoarthritis of the knee: a randomised controlled trial. *Ann Rheum Dis* 1999;58:15–19.
- 61 Péloquin L, Bravo G, Gauthier P, et al. Effects of a cross-training exercise program in persons with osteoarthritis of the knee a randomized controlled trial. J Clin Rheumatol 1999;5:126–36.
- 62 Quilty B, Tucker M, Campbell R, *et al*. Physiotherapy, including quadriceps exercises and patellar taping, for knee osteoarthritis with predominant patello-femoral joint involvement: randomized controlled trial. *J Rheumatol* 2003;30:1311–17.
- 63 Røgind H, Bibow-Nielsen B, Jensen B, et al. The effects of a physical training program on patients with osteoarthritis of the knees. Arch Physic Med Rehabil 1998;79:1421–7.
- 64 Salacinski AJ, Krohn K, Lewis SF, et al. The effects of group cycling on gait and pain-related disability in individuals with mild-to-moderate knee osteoarthritis: a randomized controlled trial. J Orthop Sports Phys Ther 2012;42:985–95.
- 65 Salli A, Sahin N, Baskent A, *et al*. The effect of two exercise programs on various functional outcome measures in patients with osteoarthritis of the knee: a randomized controlled clinical trial. *Isokin Exerc Sc* 2010;18:201–9.
- 66 Schilke JM, Johnson GO, Housh TJ, et al. Effects of muscle-strength training on the functional status of patients with osteoarthritis of the knee joint. *Nurs Res* 1996;45:68–72.
- 67 Simão AP, Avelar NC, Tossige-Gomes R, et al. Functional performance and inflammatory cytokines after squat exercises and whole-body vibration in elderly individuals with knee osteoarthritis. Arch Phys Med Rehabil 2012;93:1692–700.
- 68 Song R, Lee E-O, Lam P, et al. Effects of Tai Chi exercise on pain, balance, muscle strength, and perceived difficulties in physical functioning in older women with osteoarthritis: a randomized clinical trial. J Rheumatol 2003;30:2039–44.
- 69 Talbot LA, Gaines JM, Huynh TN, et al. A homebased pedometer-driven walking program to increase physical activity in older adults with osteoarthritis of the knee: a preliminary study. J Am Geriatr Soc 2003;51:387–92.
- 70 Thomas KS, Muir KR, Doherty M, et al. Home based exercise programme for knee pain and knee osteoarthritis: randomised controlled trial. BMJ 2002;325:752–7.
- 71 Thorstensson CA, Roos EM, Petersson IF, et al. Sixweek high-intensity exercise program for middle-aged patients with knee osteoarthritis: a randomized controlled trial [ISRCTN20244858]. BMC Musculoskelet Disord 2005;6:27.
- 72 Topp R, Woolley S, Horuyak J, et al. The effect of dynamic versus isometric resistance training on pain and functioning among adults with osteoarthritis of the knee. Arch Phys Med Rehabil 2002;83:1187–95.

- 73 van Baar ME, Dekker J, Oostendorp RAB, *et al*. The effectiveness of exercise therapy in patients with osteoarthritis of the hip or knee: a randomized clinical trial. *J Rheumatol* 1998;25:2432–9.
- 74 Wang TJ, Lee SC, Liang SY, et al. Comparing the efficacy of aquatic exercises and land-based exercises for patients with knee osteoarthritis. J Clin Nurs 2011;20:2609–22.
- 75 Yip YB, Sit JW, Fung KKY, et al. Impact of an arthritis self-management programme with an added exercise component for osteoarthritic knee sufferers on improving pain, functional outcomes, and use of health care services: an experimental study. Pat Educ Couns 2007;65:113–21.
- 76 Cohen J. *Statistical power analysis for the behavioural sciences*. New York: Academic, 1977.
- 77 Hochberg MC, Altman RD, April KT, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res 2012;64:465–74.
- 78 Zhang W, Nuki G, Moskowitz RW, et al. OARSI recommendations for the management of hip and knee osteoarthritis: Part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthr Cartil 2010;18:476–99.
- 79 Carlos KP, Belli BdS, Alfredo PP. Effect of pulsed ultrasound and continuous ultrasound linked to exercise in patients with knee osteoarthritis: pilot study [Portuguese]. *Fisioter Pesq* 2012;19:275–81.
- 80 Ghroubi S, Elleuch H, Kaffel N, et al. [Contribution of exercise and diet in the management of knee osteoarthritis in the obese]. Ann Readapt Med Phys 2008;51:663–70.
- 81 Oida Y, Morozumi K, Nakamura N, et al. [Effectiveness of a community health service program using exercise intervention for elderly people with osteoarthritis of the knees: a randomized controlled trial]. Nihon Koshu Eisei Zasshi 2008;55:228–37.
- 82 Rosa UH, Velásquez Tlapanco J, Lara Maya C, et al. [Comparison of the effectiveness of isokinetic vs isometric therapeutic exercise in patients with osteoarthritis of knee]. Reumatol Clin 2012;8:10–14.
- 83 Eungpinichpong W. The efficacy of physical exercise programmes for patients with osteoarthritis of the knee as determined by clinical and gait parameters. *New Zeal J Physiother* 1998;26:5.
- 84 Keogan F, Gilsenan C, Hussey J, et al. Open or closed chain quadriceps exercises in treatment of osteoarthritis of the knee; which is more effective? A blinded randomised controlled trial. *Physiother Ireland* 2007;28:47–8.
- 85 Uthman OA, van der Windt DÁ, Jordan JL, *et al*. Exercise for lower limb osteoarthritis: systematic review incorporating trial sequential analysis and network meta-analysis. *BMJ* 2013;347:f5555.
- 86 Juhl C, Christensen R, Roos EM, et al. Impact of exercise type and dose on pain and disability in knee osteoarthritis: a systematic review and meta-regression analysis of randomized controlled trials. Arthritis Rheumatol 2014;66:622–36.

Supplementary Table 1 Forest plot of comparison: immediate post-treatment outcome on pain.

		ercise			ontrol	1 <u></u>		Std. Mean Difference		Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% C	Year	IV, Random, 95% CI
1.1.1 Change scores										
Minor 1989	-0.6	1.9	26	-1.1	1.9	20	1.8%	0.26 [-0.33, 0.84]	1989	
Minor 1989	-0.76	1.7	49	-0.31	1.6	19	2.1%	-0.27 [-0.80, 0.27]		
Kovar 1992	-1.38	1.99	47	-0.1	2.31	45	2.7%	-0.59 [-1.01, -0.17]	1992	
Schilke 1996	-6.1	4.9	10	0.4	6.7	10	0.9%	-1.06 [-2.01, -0.11]	1996	
Bautch 1997	-1.4	2.32	15	1.03	1.55	15	1.2%	-1.20 [-1.98, -0.41]	1997	
Rogind 1998	-3	3.9	11	-0.1	6.7	12	1.1%	-0.50 [-1.34, 0.33]	1998	
van Baar 1998	-27.4	28.7	54	-11.7	28.5	59	2.9%	-0.55 [-0.92, -0.17]	1998	
Maurer 1999	-43.54	80.3	49	-28.49	80.3	49	2.8%	-0.19 [-0.58, 0.21]	1999	
Peloquin 1999	-1.44	2	59	-0.59	2.2	65	3.1%	-0.40 [-0.76, -0.04]	1999	
Hopman-Rock 2000	-0.7	24.1	45	4	21.2	37	2.6%	-0.20 [-0.64, 0.23]	2000	
Devle 2000	-129.63	91	33	-33.83	111.5	36	2.2%	-0.93 [-1.43, -0.43]	2000	
Fransen 2001	-10.6	19.5	83	1.5	19.4	43	2.9%	-0.62 [-0.99, -0.24]		
Baker 2001	-79	88	22	-20	93	22	1.8%	-0.64 [-1.25, -0.03]		
Topp 2002	-1.53	3.2	67	0.02	3.2	35	2.7%	-0.48 [-0.90, -0.07]		
Gur 2002	-20.9	8.3	17	0.7	4.6	6	0.5%	-2.74 [-4.02, -1.47]		
Huang 2003	-1.6	1.5	99	-0.4	1.6	33	2.8%	-0.78 [-1.19, -0.38]		
Song 2003	-2.45	3.9	22	0.61	5.1	21	1.7%	-0.66 [-1.28, -0.05]		
Foley 2003	-1.19	2.94	21	-0.05	2.55	20	1.7%	-0.41 [-1.02, 0.21]		
Keefe 2004	-0.7	1.69	16	0.03	1.27	18	1.5%	-0.48 [-1.17, 0.20]		
Thorstensson 2005	-1.8	1.09	30	0.03	1.27	31	2.2%	-0.14 [-0.65, 0.36]		
Bennell 2005	-1.0	1.7	73	-2	2.1	67	3.3%	-0.10 [-0.44, 0.23]		-
	-2.2	1.6	30	-0.5	1.7	32				
Huang 2005							2.2%	-0.42 [-0.92, 0.09]		
Hay 2006	-1.56	3.4	93	-0.41	2.8	89	3.5%	-0.37 [-0.66, -0.07]		
Fransen 2007	-1.67	3.28	41	-0.5	2.37	36	2.5%	-0.40 [-0.85, 0.05]		
Lim 2008	-9	12	53	-1.75	12.8	54	2.9%	-0.58 [-0.97, -0.19]		and the second
Lee 2009	-2.2	4.1	29	-0.2	1.8	15	1.7%	-0.56 [-1.20, 0.07]		
Bennell 2010	-2.6	2.6	45	-0.4	2.7	44	2.6%	-0.82 [-1.26, -0.39]		
Simao 2012	-62.5	296	11	0	35	12	1.1%	-0.29 [-1.12, 0.53]		
Chang 2012	-2.3	1.3	24 1174	-0.9	1.5	17 962	1.6%	-0.99 [-1.65, -0.33]	2012	
Subtotal (95% CI)		10.7					62.7%	-0.50 [-0.62, -0.38]		•
Heterogeneity: Tau ² = Test for overall effect: 2				.0 (F = 0	.01), 1	- 40 %				
1.1.2 End of treatmen	t scores									
Ettinger 1997a/b	2.21	0.72	146	2.46	0.61	75	3.6%	-0.36 [-0.64, -0.08]	1997	
Ettinger 1997a/b	2.14	0.6	144	2.46	0.61	75	3.6%	-0.53 [-0.81, -0.24]	1997	
Talbot 2003	1.35	0.93	17	1.2	0.95	17	1.5%	0.16 [-0.52, 0.83]	2003	
Hughes 2004	4.9	3.4	68	6.2	4.3	43	2.9%	-0.34 [-0.73, 0.04]	2004	
Brismée 2007	15.39	5.7	22	16.64	4.7	19	1.7%	-0.23 [-0.85, 0.38]		
Yip 2007	37.33	21.1	79	44.41	23.2	74	3.3%	-0.32 [-0.64, 0.00]		
An 2008		110.1	11		112.6	10	1.0%	-0.58 [-1.46, 0.30]		
Lund 2008	38	12.5	25	39.7	12	27	2.0%	-0.14 [-0.68, 0.41]		
Jan 2008	4.8	3.1	68	7.1	3.4	30	2.5%	-0.71 [-1.16, -0.27]		
Doi 2008		20.68	61	29.59	23.44	56	3.0%	-0.32 [-0.68, 0.05]		
Lin 2009	4.2	3	36	7.3	3.4	36	2.3%	-0.96 [-1.45, -0.47]		
Salli 2010	3.35	1.8	47	6.5	1.8	24	1.9%	-1.73 [-2.30, -1.16]		
Bezalel 2010	5.55	7.5	25	10	7.5	25	2.0%	-0.39 [-0.95, 0.17]		
Foroughi 2011	3.8	2.7	20	4.4	3.7	25	1.8%	-0.18 [-0.77, 0.41]		
Wang 2011	24	15	26	32	18	26	2.0%	-0.48 [-1.03, 0.08]		
Salacinski 2012	18.6	13.4	13	34.3	15.9	15	1.2%			
Salacinski 2012 Bruce-Brand 2012 Subtotal (95% CI)	10.78	4.31	10 818	8.33	4.36	6 583	0.8%	-1.03 [-1.83, -0.23] 0.54 [-0.50, 1.57] -0.47 [-0.65, -0.29]		•
Heterogeneity: Tau ² = Test for overall effect: 2			6, df = 1	6 (P = 0	.001); l ^a					
Total (95% CI)			1992			1545	100.0%	-0.49 [-0.59, -0.39]		•
Heterogeneity: Tau ² = Test for overall effect: Test for subgroup diffe	Z = 9.64 (I	P < 0.00	0001)	No.			16			-4 -2 0 2 Favours exercise Favours control

Supplementary Table 2. Forest plot of comparison: immediate post-treatment outcome on physical function

Study or Subgroup		ercise			ontrol			Std. Mean Difference		Std. Mean Difference
	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	Year	IV, Random, 95% Cl
1.2.1 Change scores										2
Minor 1989	-0.89	2.5	49	0.33	2.5	19	2.2%	-0.48 [-1.02, 0.05]		
Kovar 1992	-2.4	2.27	47	0.24	2.49	45	2.5%	-1.10 [-1.54, -0.66]	1992	
Schilke 1996	-3.66	3.3	10	-0.42	3.5	10	1.2%	-0.91 [-1.84, 0.02]	1996 -	
Bautch 1997	-2.82	7.78	15	-3.49	8.17	15	1.6%	0.08 [-0.63, 0.80]	1997	(a)
van Baar 1998	-1.3	5.7	54	-0.5	5.6	59	2.7%	-0.14 [-0.51, 0.23]	1998	3 7
Rogind 1998	-3	3.3	11	-2	5.3	12	1.4%	-0.22 [-1.04, 0.60]	1998	10 10 10 10 10
Peloquin 1999	-1.5	2.4	59	-0.54	2.6	65	2.8%	-0.38 [-0.74, -0.02]	1999	10
Maurer 1999	-106.9	390.1	49	-88.3	390.1	49	2.6%	-0.05 [-0.44, 0.35]	1999	10 10 0
Deyle 2000	-402.51	339.56	33	-98.17	393.9	36	2.3%	-0.82 [-1.31, -0.32]	2000	
Hopman-Rock 2000	-0.8	4.6	37	-1.7	5.2	34	2.4%	0.18 [-0.28, 0.65]	2000	10000000
Baker 2001	-272	295	22	-119	323	22	1.9%	-0.49 [-1.09, 0.11]	2001	Na 200 0
Fransen 2001	-7.7	19.9	83	0.1	20.5	43	2.7%	-0.39 [-0.76, -0.01]		2000
Gur 2002	-13.8	4.1	17	1	2.5	6	0.6%	-3.77 [-5.29, -2.26]	2002 4	
Topp 2002	-4.16	10.9	67	0.17	10.9	35	2.6%	-0.39 [-0.81, 0.02]		
Huang 2003	-2	1.6	99	-0.4	1.7	33	2.6%	-0.98 [-1.39, -0.57]	2003	
Song 2003	-11.09	12	22	-1.33	10.6	21	1.9%	-0.84 [-1.47, -0.22]		
Foley 2003	-2.81	7.89	21	2.1	8.1	20	1.9%	-0.60 [-1.23, 0.03]		
Bennell 2005	-7.8	8.7	73	-8.2	10	67	2.9%	0.04 [-0.29, 0.37]		
Huang 2005	-1.5	1.4	30	-0.5	1.7	32	2.2%	-0.63 [-1.14, -0.12]		
Thorstensson 2005	-2	12	30	0.6	18	31	2.3%	-0.17 [-0.67, 0.34]		
Hay 2006	-4.79	10.8	95	-0.8	8.5	90	3.0%	-0.41 [-0.70, -0.12]		
Fransen 2007	-5.04	10.25	41	2.07	9.06	36	2.4%	-0.72 [-1.19, -0.26]		
Lim 2008	-6.5	10.6	53	-2.6	10.9	54	2.7%	-0.36 [-0.74, 0.02]		
Lee 2009	-9.4	14.4	29	-2.7	10.8	15	1.9%	-0.49 [-1.13, 0.14]		
Bennell 2010	-8.07	7.7	45	-1.9	7.6	44	2.5%	-0.80 [-1.23, -0.37]		
Simao 2012	-100	740	11	75	463	12	1.4%	-0.28 [-1.10, 0.55]		
Kao 2012	3.2	34	114	1.5	20.3	91	3.1%	0.06 [-0.22, 0.33]		
Chang 2012	-10.7	5.9	24	-4.5	4.4	17	1.7%	-1.14 [-1.81, -0.47]		
Subtotal (95% CI)	10.1	0.0	1240	4.0		1013	62.0%	-0.47 [-0.63, -0.31]	2012	•
Heterodeneity: au* =	0.12; Chi ² =	= 84.69. (df = 27	(P < 0.00	0001); P	= 68%		10.2010-0. 0 .0002-0.0002-0.000		
1.19 · 가장:1976 · · · · · · · · · · · · · · · · · · ·		C 200 1990 C17094		(P < 0.00	0001); I ^z	e 68%		······································		
1.19 · 가장:1976 · · · · · · · · · · · · · · · · · · ·		C 200 1990 C17094		(P < 0.0(0001); I ^z	²= 68%				
Heterogeneity: Tau² = Test for overall effect: . 1.2.2 End of treatmen	Z= 5.78 (P	C 200 1990 C17094		(P < 0.0(0001); I ^z	²= 68%				
Test for overall effect: . 1.2.2 End of treatmen	Z= 5.78 (P	C 200 1990 C17094		(P < 0.0(1.9	0001); Iª 0.48	²= 68% 75		-0.37 [-0.66, -0.09]	1997	
Test for overall effect: .	Z = 5.78 (P t scores	< 0.0000)1)					-0.37 [-0.66, -0.09]		_
Test for overall effect: . 1.2.2 End of treatmen Ettinger 1997a/b Ettinger 1997a/b	Z = 5.78 (P t scores 1.72 1.74	< 0.0000 0.48	01) 144 144	1.9 1.9	0.48	75	3.1% 3.1%	-0.37 [-0.66, -0.09] -0.33 [-0.61, -0.05]	1997	_
Test for overall effect: . 1.2.2 End of treatmen Ettinger 1997a/b Ettinger 1997a/b Hughes 2004	Z = 5.78 (P t scores 1.72	< 0.0000 0.48 0.48	144	1.9	0.48 0.48 12.8	75 75	3.1%	-0.37 [-0.66, -0.09] -0.33 [-0.61, -0.05] -0.39 [-0.78, -0.01]	1997 2004	
Test for overall effect: . 1.2.2 End of treatmen Ettinger 1997a/b Ettinger 1997a/b Hughes 2004 Brismée 2007	Z = 5.78 (P t scores 1.72 1.74 17.3	< 0.0000 0.48 0.48 12.6)1) 144 144 68	1.9 1.9 22.3	0.48 0.48 12.8	75 75 43	3.1% 3.1% 2.7%	-0.37 [-0.66, -0.09] -0.33 [-0.61, -0.05] -0.39 [-0.78, -0.01] -0.09 [-0.71, 0.52]	1997 2004 2007	
Test for overall effect: . 1.2.2 End of treatmen Ettinger 1997a/b Ettinger 1997a/b Hughes 2004 Brismée 2007 Hurley 2007	Z = 5.78 (P t scores 1.72 1.74 17.3 39.5	< 0.0000 0.48 0.48 12.6 12.96)1) 144 144 68 22	1.9 1.9 22.3 40.69 25.9	0.48 0.48 12.8 11.89 13.6	75 75 43 19	3.1% 3.1% 2.7% 1.9%	-0.37 [-0.66, -0.09] -0.33 [-0.61, -0.05] -0.39 [-0.78, -0.01] -0.09 [-0.71, 0.52] -0.35 [-0.57, -0.12]	1997 2004 2007 2007	
Test for overall effect: . 1.2.2 End of treatmen Ettinger 1997a/b Ettinger 1997a/b Hughes 2004 Brismée 2007 Hurley 2007 An 2008	Z = 5.78 (P t scores 1.72 1.74 17.3 39.5 20 347.5	< 0.0000 0.48 0.48 12.6 12.96 18.5 383.8	144 144 68 22 229 11	1.9 1.9 22.3 40.69 25.9 511.8	0.48 0.48 12.8 11.89 13.6 381.6	75 75 43 19 113 10	3.1% 3.1% 2.7% 1.9% 3.3% 1.3%	-0.37 [-0.66, -0.09] -0.33 [-0.61, -0.05] -0.39 [-0.78, -0.01] -0.09 [-0.71, 0.52] -0.35 [-0.57, -0.12] -0.41 [-1.28, 0.46]	1997 2004 2007 2007 2008	
Test for overall effect : 1.2.2 End of treatmen Ettinger 1997a/b Ettinger 1997a/b Hughes 2004 Brismée 2007 Hurley 2007 An 2008 Jan 2008	Z = 5.78 (P t scores 1.72 1.74 17.3 39.5 20 347.5 14.8	< 0.0000 0.48 0.48 12.6 12.96 18.5)1) 144 144 68 22 229	1.9 1.9 22.3 40.69 25.9	0.48 0.48 12.8 11.89 13.6	75 75 43 19 113 10 30	3.1% 3.1% 2.7% 1.9% 3.3% 1.3% 2.5%	-0.37 [-0.66, -0.09] -0.33 [-0.61, -0.05] -0.39 [-0.78, -0.01] -0.09 [-0.71, 0.52] -0.35 [-0.57, -0.12] -0.41 [-1.28, 0.46] -0.80 [-1.24, -0.36]	1997 2004 2007 2007 2008 2008	
Test for overall effect: . 1.2.2 End of treatmen Ettinger 1997a/b Ettinger 1997a/b Hughes 2004 Brismée 2007 Hurley 2007 An 2008 Jan 2008 Lund 2008	Z = 5.78 (P t scores 1.72 1.74 17.3 39.5 20 347.5 14.8 35.9	< 0.0000 0.48 0.48 12.6 12.96 18.5 383.8 8.9 11.5	144 144 68 22 229 11 68 25	1.9 1.9 22.3 40.69 25.9 511.8 22.5 38.9	0.48 0.48 12.8 11.89 13.6 381.6 10.9 11	75 75 43 19 113 10 30 27	3.1% 3.1% 2.7% 1.9% 3.3% 1.3% 2.5% 2.1%	-0.37 [-0.66, -0.09] -0.33 [-0.61, -0.05] -0.39 [-0.78, -0.01] -0.09 [-0.71, 0.52] -0.35 [-0.57, -0.12] -0.41 [-1.28, 0.46] -0.80 [-1.24, -0.36] -0.26 [-0.81, 0.28]	1997 2004 2007 2007 2008 2008 2008	
Test for overall effect: . 1.2.2 End of treatmen Ettinger 1997a/b Ettinger 2004 Brismée 2007 Hurley 2007 An 2008 Jan 2008 Lund 2008 Doi 2008	Z = 5.78 (P t scores 1.72 1.74 17.3 39.5 20 347.5 14.8 35.9 13.69	< 0.0000 0.48 0.48 12.6 12.96 18.5 383.8 8.9 11.5 13.47	144 144 68 22 229 11 68 25 61	1.9 1.9 22.3 40.69 25.9 511.8 22.5 38.9 18.59	0.48 0.48 12.8 11.89 13.6 381.6 10.9 11 16.38	75 75 43 19 113 10 30 27 56	3.1% 3.1% 2.7% 1.9% 3.3% 1.3% 2.5% 2.1% 2.8%	-0.37 [-0.66, -0.09] -0.33 [-0.61, -0.05] -0.39 [-0.78, -0.01] -0.09 [-0.71, 0.52] -0.35 [-0.57, -0.12] -0.41 [-1.28, 0.46] -0.80 [-1.24, -0.36] -0.26 [-0.81, 0.28] -0.33 [-0.69, 0.04]	1997 2004 2007 2007 2008 2008 2008 2008	
Test for overall effect: . 1.2.2 End of treatmen Ettinger 1997a/b Ettinger 1997a/b Hughes 2004 Brismée 2007 Hurley 2007 An 2008 Jan 2008 Lund 2008 Lund 2008 Lin 2009	Z = 5.78 (P t scores 1.72 1.74 17.3 39.5 20 347.5 14.8 35.9 13.69 10.1	< 0.0000 0.48 0.48 12.6 12.96 18.5 383.8 8.9 11.5 13.47 8.3	144 144 68 22 229 11 68 25 61 36	1.9 1.9 22.3 40.69 25.9 511.8 22.5 38.9 18.59 24.9	0.48 0.48 12.8 11.89 13.6 381.6 10.9 11 16.38 11.8	75 75 43 19 113 10 30 27 56 36	3.1% 3.1% 2.7% 1.9% 3.3% 1.3% 2.5% 2.1% 2.8% 2.2%	-0.37 [-0.66, -0.09] -0.33 [-0.1, -0.05] -0.39 [-0.78, -0.01] -0.09 [-0.71, 0.52] -0.35 [-0.57, -0.12] -0.41 [-1.28, 0.46] -0.80 [-1.24, -0.36] -0.26 [-0.81, 0.28] -0.33 [-0.69, 0.04] -1.44 [-1.96, -0.91]	1997 2004 2007 2007 2008 2008 2008 2008 2008 2008	
Test for overall effect: . 1.2.2 End of treatmen Ettinger 1997a/b Ettinger 1997a/b Hughes 2004 Brismée 2007 Hurley 2007 An 2008 Jan 2008 Lund 2008 Lund 2008 Lin 2009 Jan 2009	Z = 5.78 (P t scores 1.72 1.74 17.3 39.5 20 347.5 14.8 35.9 13.69 10.1 11.2	< 0.0000 0.48 0.48 12.6 12.96 18.5 383.8 8.9 11.5 13.47 8.3 10.1	144 144 68 22 229 11 68 25 61 36 71	1.9 1.9 22.3 40.69 25.9 511.8 22.5 38.9 18.59 24.9 25	0.48 0.48 12.8 11.89 13.6 381.6 10.9 11 16.38 11.8 11.8	75 75 43 19 113 30 27 56 36 36 35	3.1% 3.1% 2.7% 1.9% 3.3% 2.5% 2.1% 2.8% 2.2% 2.2%	-0.37 [-0.66, -0.09] -0.33 [-0.78, -0.05] -0.39 [-0.78, -0.01] -0.09 [-0.71, 0.52] -0.35 [-0.57, -0.12] -0.41 [-1.28, 0.46] -0.80 [-1.24, -0.36] -0.26 [-0.81, 0.28] -0.33 [-0.69, 0.04] -1.44 [-1.96, -0.91] -1.28 [-1.72, -0.84]	1997 2004 2007 2007 2008 2008 2008 2008 2008 2009 — 2009	
Test for overall effect: . 1.2.2 End of treatmen Ettinger 1997a/b Ettinger 1997a/b Hughes 2004 Brismée 2007 Hurley 2007 An 2008 Jan 2008 Lund 2008 Lund 2008 Lin 2009 Jan 2009 Salli 2010	Z = 5.78 (P t scores 1.72 1.74 17.3 39.5 20 347.5 14.8 35.9 13.69 10.1 11.2 20.65	< 0.0000 0.48 0.48 12.6 12.96 18.5 383.8 8.9 11.5 13.47 8.3 10.1 8.9	11) 144 144 68 22 229 11 68 25 61 36 71 47	1.9 1.9 22.3 40.69 25.9 511.8 22.5 38.9 18.59 24.9 25 32.6	0.48 0.48 12.8 13.6 381.6 10.9 11 16.38 11.8 11.8 11.8 11.6	75 75 43 19 113 30 27 56 36 35 24	3.1% 3.1% 2.7% 1.9% 1.3% 2.5% 2.1% 2.8% 2.2% 2.5% 2.2%	-0.37 [-0.66, -0.09] -0.33 [-0.61, -0.05] -0.39 [-0.78, -0.01] -0.09 [-0.71, 0.52] -0.35 [-0.57, -0.12] -0.41 [-1.28, 0.46] -0.80 [-1.24, -0.36] -0.26 [-0.81, 0.28] -0.33 [-0.69, 0.04] -1.44 [-1.96, -0.91] -1.28 [-1.72, -0.84] -1.20 [-1.73, -0.66]	1997 2004 2007 2008 2008 2008 2008 2008 2008 2009 2009	
Test for overall effect: . 1.2.2 End of treatmen Ettinger 1997a/b Ettinger 1997a/b Hughes 2004 Brismée 2007 Hurley 2007 An 2008 Jan 2008 Lund 2008 Lund 2008 Lin 2009 Jan 2009 Salli 2010 Bezalel 2010	Z = 5.78 (P t scores 1.72 1.74 17.3 39.5 20 347.5 14.8 35.9 13.69 10.1 11.2 20.65 25	< 0.0000 0.48 0.48 12.6 18.5 383.8 8.9 11.5 13.47 8.3 10.1 8.9 10.1	11) 144 144 68 22 229 11 68 25 61 36 71 47 25	1.9 1.9 22.3 40.69 25.9 511.8 22.5 38.9 18.59 24.9 25 32.6 32.6 34	0.48 0.48 12.8 11.89 13.6 381.6 10.9 11 16.38 11.8 11.8 11.8 11.6 10	75 75 43 19 113 30 27 56 36 35 24 25	3.1% 3.1% 2.7% 1.9% 3.3% 2.5% 2.1% 2.8% 2.2% 2.2% 2.2% 2.2% 2.2%	-0.37 [-0.66, -0.09] -0.33 [-0.61, -0.05] -0.39 [-0.78, -0.01] -0.09 [-0.71, 0.52] -0.35 [-0.57, -0.12] -0.41 [-1.28, 0.46] -0.80 [-1.24, -0.36] -0.26 [-0.81, 0.28] -0.33 [-0.69, 0.04] -1.44 [-1.96, -0.91] -1.28 [-1.72, -0.84] -0.39 [-1.47, -0.30]	1997 2004 2007 2008 2008 2008 2008 2008 2009 2009 2010 2010	
Test for overall effect: . 1.2.2 End of treatmen Ettinger 1997a/b Ettinger 1997a/b Hughes 2004 Brismée 2007 Hurley 2007 An 2008 Jan 2008 Lund 2008 Lund 2008 Lin 2009 Jan 2009 Salli 2010 Bezalel 2010 Foroughi 2011	Z = 5.78 (P t scores 1.72 1.74 17.3 39.5 20 347.5 14.8 35.9 13.69 10.1 11.2 20.65 25 13.3	< 0.0000 0.48 0.48 12.6 18.5 383.8 8.9 11.5 13.47 8.3 10.1 8.9 10.1 8.9 10.1	144 144 68 22 229 11 68 25 61 36 71 47 25 20	1.9 1.9 22.3 40.69 25.9 511.8 22.5 38.9 18.59 24.9 25 32.6 32.6 34 18.1	0.48 0.48 12.8 11.89 13.6 381.6 10.9 11 16.38 11.8 11.8 11.8 11.6 10 12	75 75 43 19 113 30 27 56 36 35 24 25 25	3.1% 3.1% 2.7% 1.9% 3.3% 1.3% 2.5% 2.1% 2.8% 2.2% 2.5% 2.2% 2.0% 2.0%	-0.37 [-0.66, -0.09] -0.33 [-0.61, -0.05] -0.39 [-0.78, -0.01] -0.09 [-0.71, 0.52] -0.35 [-0.57, -0.12] -0.41 [-1.28, 0.46] -0.26 [-0.81, 0.28] -0.33 [-0.69, 0.04] -1.44 [-1.96, -0.91] -1.28 [-1.72, -0.84] -1.20 [-1.73, -0.66] -0.89 [-1.47, -0.30] -0.43 [-1.03, 0.16]	1997 2004 2007 2008 2008 2008 2008 2008 2009 2009 2010 2010 2011	
Test for overall effect: . 1.2.2 End of treatmen Ettinger 1997a/b Ettinger 1997a/b Hughes 2004 Brismée 2007 Hurley 2007 An 2008 Jan 2008 Lund 2008 Lund 2008 Doi 2008 Lin 2009 Jan 2009 Salli 2010 Bezalel 2010 Foroughi 2011 Wang 2011	Z = 5.78 (P t scores 1.72 1.74 17.3 39.5 20 347.5 14.8 35.9 13.69 10.1 11.2 20.65 25 13.3 18	< 0.0000 0.48 0.48 12.6 12.96 18.5 383.8 8.9 11.5 13.47 8.3 10.1 8.9 10.1 8.9 10.1 8.9 10	11) 144 144 68 22 229 11 68 25 61 36 71 47 25 20 26	1.9 1.9 22.3 40.69 25.9 511.8 22.5 38.9 18.59 24.9 25 32.6 34 18.1 31	0.48 0.48 12.8 11.89 13.6 381.6 10.9 11 16.38 11.8 11.8 11.8 11.8 11.6 10 12 18	75 75 43 19 113 30 27 56 35 24 25 25 26	3.1% 3.1% 2.7% 1.9% 3.3% 1.3% 2.5% 2.1% 2.8% 2.2% 2.2% 2.2% 2.2% 2.0% 2.0% 2.1%	-0.37 [-0.66, -0.09] -0.33 [-0.78, -0.01] -0.09 [-0.78, -0.01] -0.09 [-0.77, 0.52] -0.35 [-0.57, -0.12] -0.41 [-1.28, 0.46] -0.80 [-1.24, -0.36] -0.26 [-0.81, 0.28] -0.33 [-0.69, 0.04] -1.44 [-1.96, -0.91] -1.28 [-1.72, -0.84] -1.20 [-1.73, -0.66] -0.89 [-1.47, -0.30] -0.43 [-1.03, 0.16] -0.79 [-1.36, -0.23]	1997 2004 2007 2008 2008 2008 2008 2008 2009 2009 2010 2010 2011 2011	
Test for overall effect: . 1.2.2 End of treatmen Ettinger 1997a/b Ettinger 1997a/b Hughes 2004 Brismée 2007 An 2008 Jan 2008 Lund 2008 Lin 2009 Jan 2009 Salli 2010 Bezalel 2010 Foroughi 2011 Wang 2011 Salacinski 2012	Z = 5.78 (P t scores 1.72 1.74 17.3 39.5 20 347.5 14.8 35.9 13.69 10.1 11.2 20.65 25 13.3 18 15.8	< 0.0000 0.48 0.48 12.6 12.96 18.5 383.8 8.9 11.5 13.47 8.3 10.1 8.9 10 9.4 14 13.9	11) 144 144 68 22 229 11 68 25 61 36 61 36 71 47 25 20 26 13	1.9 1.9 22.3 40.69 25.9 511.8 22.5 38.9 18.59 24.9 25 32.6 34 18.1 31 28.9	0.48 0.48 12.8 11.89 13.6 381.6 10.9 11 16.38 11.8 11.8 11.8 11.8 11.6 10 12 18 16.2	75 75 43 19 113 30 27 56 35 24 25 25 26 15	3.1% 3.1% 2.7% 1.9% 3.3% 1.3% 2.5% 2.1% 2.2% 2.2% 2.2% 2.2% 2.0% 2.0% 2.1% 1.5%	-0.37 [-0.66, -0.09] -0.33 [-0.78, -0.01] -0.09 [-0.74, 0.52] -0.35 [-0.57, -0.12] -0.41 [-1.28, 0.46] -0.80 [-1.24, -0.36] -0.26 [-0.81, 0.28] -0.33 [-0.69, 0.04] -1.44 [-1.96, -0.91] -1.28 [-1.72, -0.84] -1.20 [-1.73, -0.66] -0.89 [-1.47, -0.30] -0.43 [-1.03, 0.16] -0.79 [-1.36, -0.23] -0.84 [-1.62, -0.06]	1997 2004 2007 2008 2008 2008 2008 2008 2009 2009 2010 2010 2011 2011 2011 2012	
Test for overall effect: . 1.2.2 End of treatmen Ettinger 1997a/b Ettinger 1997a/b Hughes 2004 Brismée 2007 An 2008 Jan 2008 Lund 2008 Lund 2008 Lin 2009 Salli 2010 Bezalel 2010 Foroughi 2011 Wang 2011 Salacinski 2012 Bruce-Brand 2012	Z = 5.78 (P t scores 1.72 1.74 17.3 39.5 20 347.5 14.8 35.9 13.69 10.1 11.2 20.65 25 13.3 18	< 0.0000 0.48 0.48 12.6 12.96 18.5 383.8 8.9 11.5 13.47 8.3 10.1 8.9 10.1 8.9 10.1 8.9 10	144 144 68 229 11 68 25 61 36 71 47 25 20 26 13 10	1.9 1.9 22.3 40.69 25.9 511.8 22.5 38.9 18.59 24.9 25 32.6 34 18.1 31 28.9	0.48 0.48 12.8 11.89 13.6 381.6 10.9 11 16.38 11.8 11.8 11.8 11.8 11.6 10 12 18	75 75 43 19 10 30 27 56 36 35 24 25 25 26 15 6	3.1% 3.1% 2.7% 1.9% 3.3% 2.5% 2.5% 2.5% 2.2% 2.2% 2.2% 2.0% 2.0% 2.0% 2.1% 1.5% 1.0%	-0.37 [-0.66, -0.09] -0.33 [-0.61, -0.05] -0.39 [-0.78, -0.01] -0.09 [-0.71, 0.52] -0.35 [-0.57, -0.12] -0.41 [-1.28, 0.46] -0.80 [-1.24, -0.36] -0.26 [-0.81, 0.28] -0.33 [-0.69, 0.04] -1.44 [-1.96, -0.91] -1.28 [-1.72, -0.84] -1.20 [-1.73, -0.66] -0.89 [-1.47, -0.30] -0.43 [-1.03, 0.16] -0.79 [-1.36, -0.23] -0.84 [-1.62, -0.06] 0.53 [-0.50, 1.57]	1997 2004 2007 2008 2008 2008 2008 2008 2009 2009 2010 2010 2011 2011 2011 2012	
Test for overall effect: . 1.2.2 End of treatmen Ettinger 1997a/b Ettinger 1997a/b Hughes 2004 Brismée 2007 Hurley 2007 An 2008 Jan 2008 Lund 2008 Lund 2008 Lund 2008 Lin 2009 Salli 2010 Bezalel 2010 Foroughi 2011 Wang 2011 Salacinski 2012 Bruce-Brand 2012 Subtotal (95% CI) Heterogeneity: Tau ² =	Z = 5.78 (P t scores 1.72 1.74 17.3 39.5 20 347.5 14.8 35.9 13.69 10.1 11.2 20.65 25 13.3 18 15.8 33.91 0.10; Chi [≈] =	< 0.0000 0.48 0.48 12.6 18.56 18.56 18.58 8.9 11.5 13.47 8.3 10.1 8.9 10.9 9.4 14 13.9 12.91 = 47.46, 4	11) 144 144 68 229 11 68 25 61 36 71 47 25 20 13 10 1020 df = 16	1.9 1.9 22.3 40.69 25.9 511.8 22.5 38.9 18.59 24.9 25 32.6 34 18.1 31 28.9 26.11	0.48 0.48 12.8 11.89 13.6 381.6 10.9 11 16.38 11.8 11.8 11.8 11.6 12 18 16.2 15.33	75 43 19 113 30 27 56 36 35 24 25 25 26 6 640	3.1% 3.1% 2.7% 1.9% 3.3% 1.3% 2.5% 2.1% 2.2% 2.2% 2.2% 2.2% 2.0% 2.0% 2.1% 1.5%	-0.37 [-0.66, -0.09] -0.33 [-0.78, -0.01] -0.09 [-0.74, 0.52] -0.35 [-0.57, -0.12] -0.41 [-1.28, 0.46] -0.80 [-1.24, -0.36] -0.26 [-0.81, 0.28] -0.33 [-0.69, 0.04] -1.44 [-1.96, -0.91] -1.28 [-1.72, -0.84] -1.20 [-1.73, -0.66] -0.89 [-1.47, -0.30] -0.43 [-1.03, 0.16] -0.79 [-1.36, -0.23] -0.84 [-1.62, -0.06]	1997 2004 2007 2008 2008 2008 2008 2008 2009 2009 2010 2010 2011 2011 2011 2012	
Test for overall effect: . 1.2.2 End of treatmen Ettinger 1997a/b Ettinger 1997a/b Hughes 2004 Brismée 2007 Hurley 2007 An 2008 Lund 2008 Lund 2008 Lund 2008 Lin 2009 Salli 2010 Bezalel 2010 Foroughi 2011 Wang 2011 Salacinski 2012 Bruce-Brand 2012 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: .	Z = 5.78 (P t scores 1.72 1.74 17.3 39.5 20 347.5 14.8 35.9 13.69 10.1 11.2 20.65 25 13.3 18 15.8 33.91 0.10; Chi [≈] =	< 0.0000 0.48 0.48 12.6 18.56 18.56 18.58 8.9 11.5 13.47 8.3 10.1 8.9 10.9 9.4 14 13.9 12.91 = 47.46, 4	144 144 68 229 11 68 25 61 36 71 47 25 20 26 13 10 1020 cff = 16 01)	1.9 1.9 22.3 40.69 25.9 511.8 22.5 38.9 18.59 24.9 25 32.6 34 18.1 31 28.9 26.11	0.48 0.48 12.8 11.89 13.6 381.6 10.9 11 16.38 11.8 11.8 11.8 11.6 12 18 16.2 15.33	75 75 43 19 113 30 27 56 36 35 24 25 26 25 26 15 6 60 = 66%	3.1% 3.1% 2.7% 1.9% 3.3% 2.5% 2.1% 2.8% 2.2% 2.2% 2.2% 2.0% 2.0% 2.1% 1.5% 1.0% 38.0%	-0.37 [-0.66, -0.09] -0.33 [-0.61, -0.05] -0.39 [-0.78, -0.01] -0.09 [-0.71, 0.52] -0.35 [-0.57, -0.12] -0.41 [-1.28, 0.46] -0.80 [-1.24, -0.36] -0.26 [-0.81, 0.28] -0.33 [-0.69, 0.04] -1.44 [-1.96, -0.91] -1.28 [-1.72, -0.84] -1.20 [-1.73, -0.66] -0.89 [-1.47, -0.30] -0.43 [-1.03, 0.16] -0.79 [-1.36, -0.23] -0.84 [-1.62, -0.06] 0.53 [-0.50, 1.57] -0.59 [-0.78, -0.40]	1997 2004 2007 2008 2008 2008 2008 2008 2009 2009 2010 2010 2011 2011 2011 2012	
Test for overall effect: . 1.2.2 End of treatmen Ettinger 1997a/b Ettinger 1997a/b Hughes 2004 Brismée 2007 Hurley 2007 An 2008 Lund 2008 Lund 2008 Lund 2008 Lund 2008 Lund 2008 Salli 2010 Bezalel 2010 Foroughi 2011 Salacinski 2012 Bruce-Brand 2012 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: .	Z = 5.78 (P t scores 1.72 1.74 17.3 39.5 20 347.5 14.8 35.9 13.69 10.1 11.2 20.65 25 13.3 18 15.8 33.91 0.10; Chi≆ Z = 6.00 (P	< 0.0000 0.48 0.48 12.6 12.96 18.5 3838.9 11.5 13.47 8.3 10.1 8.9 10.9 9.4 13.9 12.91 = 47.46, < < 0.0000	144 144 68 22 229 11 68 25 61 36 71 47 25 20 26 13 10 1020 cff = 16 01) 2260	1.9 1.9 22.3 40.69 25.9 511.8 22.5 38.9 18.59 24.9 25 32.6 34 18.1 31 28.9 26.11 (P < 0.0(0.48 0.48 12.8 11.89 13.6 381.6 10.9 11 16.38 11.8 11.8 11.6 10 12 18 16.2 15.33	75 75 43 19 113 30 27 56 36 35 24 25 25 26 15 6 640 = 66%	3.1% 3.1% 2.7% 1.9% 3.3% 2.5% 2.1% 2.8% 2.2% 2.2% 2.2% 2.0% 2.2% 2.0% 2.1% 3.0% 38.0%	-0.37 [-0.66, -0.09] -0.33 [-0.61, -0.05] -0.39 [-0.78, -0.01] -0.09 [-0.71, 0.52] -0.35 [-0.57, -0.12] -0.41 [-1.28, 0.46] -0.80 [-1.24, -0.36] -0.26 [-0.81, 0.28] -0.33 [-0.69, 0.04] -1.44 [-1.96, -0.91] -1.28 [-1.72, -0.84] -1.20 [-1.73, -0.66] -0.89 [-1.47, -0.30] -0.43 [-1.03, 0.16] -0.79 [-1.36, -0.23] -0.84 [-1.62, -0.06] 0.53 [-0.50, 1.57]	1997 2004 2007 2008 2008 2008 2008 2008 2009 2009 2010 2010 2011 2011 2011 2012	
Test for overall effect: . 1.2.2 End of treatmen Ettinger 1997a/b Ettinger 1997a/b Hughes 2004 Brismée 2007 Hurley 2007 An 2008 Lund 2008 Lund 2008 Lund 2008 Lin 2009 Salli 2010 Bezalel 2010 Foroughi 2011 Wang 2011 Salacinski 2012 Bruce-Brand 2012 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: .	Z = 5.78 (P t scores 1.72 1.74 17.3 39.5 20 347.5 14.8 35.9 13.69 10.1 11.2 20.65 25 13.3 18 15.8 33.91 0.10; Chi≇= Z = 6.00 (P	< 0.0000 0.48 0.48 12.6 12.96 18.5 383.8 8.9 11.5 13.47 8.3 10.1 8.9 10.9 4 13.9 12.91 = 47.46, < 0.0000	144 144 68 22 229 11 68 25 61 36 71 47 25 20 26 13 10 20 26 13 10 1020 df = 16 11) 2260 , df = 44	1.9 1.9 22.3 40.69 25.9 511.8 22.5 38.9 18.59 24.9 25 32.6 34 18.1 31 28.9 26.11 (P < 0.0(0.48 0.48 12.8 11.89 13.6 381.6 10.9 11 16.38 11.8 11.8 11.6 10 12 18 16.2 15.33	75 75 43 19 113 30 27 56 36 35 24 25 25 26 15 6 640 = 66%	3.1% 3.1% 2.7% 1.9% 3.3% 2.5% 2.1% 2.8% 2.2% 2.2% 2.2% 2.0% 2.2% 2.0% 2.1% 3.0% 38.0%	-0.37 [-0.66, -0.09] -0.33 [-0.61, -0.05] -0.39 [-0.78, -0.01] -0.09 [-0.71, 0.52] -0.35 [-0.57, -0.12] -0.41 [-1.28, 0.46] -0.80 [-1.24, -0.36] -0.26 [-0.81, 0.28] -0.33 [-0.69, 0.04] -1.44 [-1.96, -0.91] -1.28 [-1.72, -0.84] -1.20 [-1.73, -0.66] -0.89 [-1.47, -0.30] -0.43 [-1.03, 0.16] -0.79 [-1.36, -0.23] -0.84 [-1.62, -0.06] 0.53 [-0.50, 1.57] -0.59 [-0.78, -0.40]	1997 2004 2007 2008 2008 2008 2008 2008 2009 2009 2010 2010 2011 2011 2011 2012	

Supplementary Table 3 Forest plot of comparison: immediate post-treatment outcome on quality of life.

	Ex	kercise		0	Control			Std. Mean Difference		Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	Year	IV, Random, 95% Cl
1.3.1 Change scores										C.
Minor 1989	-1.7	1.3	28	-2.4	1.7	28	5.3%	0.46 [-0.07, 0.99]	1989	
Fransen 2001	2	6.4	83	-0.7	3.7	43	10.7%	0.48 [0.10, 0.85]	2001	
Keefe 2004	0.38	1.22	16	0.05	0.33	18	3.2%	0.37 [-0.31, 1.05]	2004	
Thorstensson 2005	4	13	30	-0.7	14	31	5.8%	0.34 [-0.16, 0.85]	2005	
Bennell 2005	0.5	0.13	73	0.51	0.17	67	13.5%	-0.07 [-0.40, 0.27]	2005	
Hay 2006	0.14	2	93	-0.28	2	89	17.5%	0.21 [-0.08, 0.50]	2006	
Lee 2009	19.2	15.9	29	9.1	10.3	15	3.6%	0.69 [0.05, 1.34]	2009	
Kao 2012 Subtotal (95% CI)	2.1	9.3	114 466	-0.33	7.9	91 382	19.4% 78.8 %	0.28 [0.00, 0.55] 0.27 [0.13, 0.42]	2012	•
Heterogeneity: Tau ^z =	0.00° Ch	$ni^2 = 7.6$	1 df=	7 (P = 0)	37): 12=	8%				
1.3.2 End of treatmer	nt scores	6								
Fransen 2007	49.61	8.83	41	47.6	8.2	36	7.4%	0.23 [-0.22, 0.68]	2007	
Lund 2008	43.8	12.5	25	43.1	11.5	27	5.0%	0.06 [-0.49, 0.60]	2008	
Wang 2011	74	11	26	67	13	26	4.8%	0.57 [0.02, 1.13]	2011	
Salacinski 2012	59.2	17.5	13	46.7	22.6	15	2.6%	0.59 [-0.17, 1.36]	2012	100 00 00 00 00 00 00 00 00 00 00 00 00
Bruce-Brand 2012 Subtotal (95% Cl)	66.64	20.36	10 115	65	27.77	6 110	1.4% 21.2 %	0.07 [-0.95, 1.08] 0.30 [0.04, 0.57]	2012	
23832	0.00.04				C () . 17		21.270	0.50 [0.04, 0.57]		-
Heterogeneity: Tau ² =			0.000	4 (P = 0.	04);1*=	0%				
Test for overall effect:	Z= 2.23	(P=0.0	(3)							
Total (95% CI)			581			492	100.0%	0.28 [0.15, 0.40]		◆
Heterogeneity: Tau ^z =	0.00; Cł	ni = 10.	20, df=	12 (P =	0.60);	² = 0%			-2	
Test for overall effect:	Z=4.45	(P < 0.0	00001)						-2	-1 U 1 Favours control Favours exercise
Test for subaroup diff					0.000	17 000				ravours control ravours exercise